The Supreme Court unanimously ruled that Amarin Pharma failed to state a viable induced-infringement claim against Hikma's skinny-label generic Vascepa, raising the pleading bar for brand drugmakers.
The U.S. Supreme Court reversed the Federal Circuit on June 4, ruling unanimously that Amarin Pharma failed to plausibly allege that Hikma Pharmaceuticals actively induced infringement of Amarin's cardiovascular patents through its skinny-label generic version of Vascepa [1]. Justice Ketanji Brown Jackson authored the opinion, holding that a brand manufacturer must point to affirmative, unambiguous steps by a generic maker that encourage infringement, and that ambiguous communications or market conduct alone cannot carry an induced-infringement claim past the pleading stage [1][2].
The case, *Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.*, No. 24-889, reached the Court after the Federal Circuit had allowed Amarin's induced-infringement claim to survive dismissal [3]. Amarin markets Vascepa as a treatment for elevated triglycerides and holds patents covering a later-approved cardiovascular indication. Hikma sought approval under the Hatch-Waxman Act using a so-called skinny label, which carves out patented uses from the generic's labeling, confining the approved indication to the unpatented triglyceride indication [2][3]. Amarin argued that Hikma's marketing conduct nonetheless encouraged physicians to prescribe the generic for the patented cardiovascular use [1].
The Court's holding recalibrates the pleading standard for induced infringement in the Hatch-Waxman context. To survive a motion to dismiss, a brand plaintiff must allege specific, affirmative acts by the generic manufacturer that clearly promote the infringing use, not merely circumstantial inferences drawn from the generic's market presence or general promotional activity [1][3]. The decision validates the statutory skinny-label carveout as a genuine safe harbor when a generic manufacturer stays within the boundaries of its FDA-authorized label [2]. For patent litigators, the ruling forecloses a line of pleading strategy that brand manufacturers had used to delay generic entry by attaching infringement liability to routine commercial conduct [1].
The decision's practical reach extends beyond Hikma and Amarin. Generic manufacturers across the industry had watched the case as a test of whether skinny-label approvals could provide durable protection against induced-infringement suits at the threshold stage [2]. Brand manufacturers now face the challenge of identifying concrete, label-independent promotional acts before filing suit, a burden that will require more developed pre-litigation investigation [1]. Observers expect the ruling to accelerate generic entry timelines in therapeutic categories where brand manufacturers hold secondary-indication patents while the primary indication has entered the public domain [2][3].
—